Abstract
Helicobacter pylori is among the major pathogenic bacteria that cause chronic gastritis and peptic ulcer disease and is related to the development of gastric cancer. Several chemicals, including antibiotics, have been used to eradicate H. pylori; however, they do not always curb the infection. Ten representative type strains of lactic acid bacteria (LAB) were screened for antagonism toward H. pylori via inhibition of urease activity. Strains inhibiting the binding of H. pylori to human gastric cell line cells and suppressing H. pylori-induced interleukin-8 (IL-8) production were also screened. Of these, Pediococcus pentosaseus (SL4), which inhibited the adhesion of H. pylori to MKN-45 gastric cancer cells, Bifidobacterium longum (BG7), with urease inhibiting activity, and Lactococcus lactis (SL3), and Enterococcus faecalis (SL5), which suppressed H. pylori-induced IL-8 production within MKN-45 and AGS cells, were selected. In mouse model, these LAB stains in combination significantly suppressed IL-8 levels in serum. Gastric pH also recovered to normal values after the administration of these LAB. These stains effectively suppressed H. pylori viability, although not to the extent of antibiotic treatment. When used as probiotics, LAB may help decrease the occurrence of gastritis and reduce the risk of H. pylori infection without, inducing side effects.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Aiba Y., Suzuki N., Kabir A.M., Takagi A., and Koga Y. 1998. Lactic acid-mediated suppression of Helicobacter pylori by the oral administration of Lactobacillus salivarius as a probiotic in a gnotobiotic murine model. Am. J. Gastroenterol. 93, 2097–2101.
Aydin A., Onder G.F., Akarca U.S., Tekin F., Tuncyurek M., and Musoglu A. 2005. The efficacy of two-week therapy with ranitidine bismuth citrate, amoxicillin and clarithromycin on Helicobacter pylori eradication in clarithromycinresistant and- sensitive cases. Turk. J. Gastroenterol. 16, 203–206.
Boonyaritichaikij S., Kuwabara K., Nagano J., Kobayashi K., and Koga Y. 2009. Long-term administration of probiotics to asymptomatic pre-school children for either the eradication or the prevention of Helicobacter pylori infection. Helicobacter 14, 202–207.
Chey W.D., Wong B.C., and Practice Parameters Committee of the American College of, G. 2007. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am. J. Gastroenterol. 102, 1808–1825.
Coconnier M.H., Lievin V., Hemery E., and Servin A.L. 1998. Antagonistic activity against Helicobacter infection in vitro and in vivo by the human Lactobacillus acidophilus strain LB. Appl. Environ. Microbiol. 64, 4573–4580.
Corr S.C., Gahan C.G., and Hill C. 2007. Impact of selected Lactobacillus and Bifidobacterium species on Listeria monocytogenes infection and the mucosal immune response. FEMS Immunol. Med. Microbiol. 50, 380–388.
Cremonini F., Di Caro S., Covino M., Armuzzi A., Gabrielli M., Santarelli L., Nista E.C., Cammarota G., Gasbarrini G., and Gasbarrini A. 2002. Effect of different probiotic preparations on anti-Helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study. Am. J. Gastroenterol. 97, 2744–2749.
De Keersmaecker S.C., Verhoeven T.L., Desair J., Marchal K., Vanderleyden J., and Nagy I. 2006. Strong antimicrobial activity of Lactobacillus rhamnosus GG against Salmonella typhimurium is due to accumulation of lactic acid. FEMS Microbiol. Lett. 259, 89–96.
Fernandez M.F., Boris S., and Barbes C. 2003. Probiotic properties of human lactobacilli strains to be used in the gastrointestinal tract. J. Appl. Microbiol. 94, 449–455.
Gotteland M., Brunser O., and Cruchet S. 2006. Systematic review: are probiotics useful in controlling gastric colonization by Helicobacter pylori? Aliment. Pharmacol. Ther. 23, 1077–1086.
Hamilton-Miller J.M. 2003. The role of probiotics in the treatment and prevention of Helicobacter pylori infection. Int. J. Antimicrob. Agents 22, 360–366.
Hazell S.L., Borody T.J., Gal A., and Lee A. 1987. Campylobacter pyloridis gastritis I: Detection of urease as a marker of bacterial colonization and gastritis. Am. J. Gastroenterol. 82, 292–296.
Hsieh P.S., Tsai Y.C., Chen Y.C., Teh S.F., Ou C.M., and King V.A. 2012. Eradication of Helicobacter pylori infection by the probiotic strains Lactobacillus johnsonii MH-68 and L. salivarius ssp. salicinius AP-32. Helicobacter 17, 466–477.
Ierardi E., Giorgio F., Losurdo G., Di Leo A., and Principi M. 2013. How antibiotic resistances could change treatment: A matter of geography? World J. Gastroenterol. 19, 8168–8180.
Innocenti M., Thoreson A.C., Ferrero R.L., Stromberg E., Bolin I., Eriksson L., Svennerholm A.M., and Quiding-Jarbrink M. 2002. Helicobacter pylori-induced activation of human endothelial cells. Infect. Immun. 70, 4581–4590.
Johnson-Henry K.C., Mitchell D.J., Avitzur Y., Galindo-Mata E., Jones N.L., and Sherman P.M. 2004. Probiotics reduce bacterial colonization and gastric inflammation in H. pylori-infected mice. Dig. Dis. Sci. 49, 1095–1102.
Johnson-Henry K.C., Nadjafi M., Avitzur Y., Mitchell D.J., Ngan B.Y., Galindo-Mata E., Jones N.L., and Sherman P.M. 2005. Amelioration of the effects of Citrobacter rodentium infection in mice by pretreatment with probiotics. J. Infect. Dis. 191, 2106–2117.
Joseph I.M. and Kirschner D. 2004. A model for the study of Helicobacter pylori interaction with human gastric acid secretion. J. Theor. Biol. 228, 55–80.
Kabir A.M., Aiba Y., Takagi A., Kamiya S., Miwa T., and Koga Y. 1997. Prevention of Helicobacter pylori infection by lactobacilli in a gnotobiotic murine model. Gut 41, 49–55.
Kamiji M.M. and de Oliveira R.B. 2005. Non-antibiotic therapies for Helicobacter pylori infection. Eur. J. Gastroenterol. Hepatol. 17, 973–981.
Kim M.N., Kim N., Lee S.H., Park Y.S., Hwang J.H., Kim J.W., Jeong S.H., Lee D.H., Kim J.S., Jung H.C., and Song I.S. 2008. The effects of probiotics on PPI-triple therapy for Helicobacter pylori eradication. Helicobacter 13, 261–268.
Kuwahara H., Miyamoto Y., Akaike T., Kubota T., Sawa T., Okamoto S., and Maeda H. 2000. Helicobacter pylori urease suppresses bactericidal activity of peroxynitrite via carbon dioxide production. Infect. Immun. 68, 4378–4383.
Lee A., O’Rourke J., De Ungria M.C., Robertson B., Daskalopoulos G., and Dixon M.F. 1997. A standardized mouse model of Helicobacter pylori infection: introducing the Sydney strain. Gastroenterology 112, 1386–1397.
Lind T., Megraud F., Unge P., Bayerdorffer E., O’Morain C., Spiller R., Veldhuyzen Van Zanten S., Bardhan K.D., Hellblom M., Wrangstadh M., and et al. 1999. The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology 116, 248–253.
Lionetti E., Indrio F., Pavone L., Borrelli G., Cavallo L., and Francavilla R. 2010. Role of probiotics in pediatric patients with Helicobacter pylori infection: a comprehensive review of the literature. Helicobacter 15, 79–87.
Mack D.R., Michail S., Wei S., McDougall L., and Hollingsworth M.A. 1999. Probiotics inhibit enteropathogenic E. coli adherence in vitro by inducing intestinal mucin gene expression. Am. J. Physiol. 276, G941–950.
Maeda S., Yoshida H., Matsunaga H., Ogura K., Kawamata O., Shiratori Y., and Omata M. 2000. Detection of clarithromycinresistant Helicobacter pylori strains by a preferential homoduplex formation assay. J. Clin. Microbiol. 38, 210–214.
Maeda S., Yoshida H., Ogura K., Kanai F., Shiratori Y., and Omata M. 1998. Helicobacter pylori specific nested PCR assay for the detection of 23S rRNA mutation associated with clarithromycin resistance. Gut 43, 317–321.
Malfertheiner P., Megraud F., O’Morain C., Bazzoli F., El-Omar E., Graham D., Hunt R., Rokkas T., Vakil N., and Kuipers E.J. 2007. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 56, 772–781.
Marshall B.J. 1994. Helicobacter pylori. Am. J. Gastroenterol. 89, S116–128.
Matsumoto M., Hara K., and Benno Y. 2007. The influence of the immunostimulation by bacterial cell components derived from altered large intestinal microbiota on probiotic anti-inflammatory benefits. FEMS Immunol. Med. Microbiol. 49, 387–390.
Nam H., Ha M., Bae O., and Lee Y. 2002. Effect of Weissella confusa strain PL9001 on the adherence and growth of Helicobacter pylori. Appl. Environ. Microbiol. 68, 4642–4645.
Ohana M., Okazaki K., Oshima C., Kawasaki K., Fukui T., Tamaki H., Matsuura M., Asada M., Nishi T., Uchida K., and et al. 2003. Inhibitory effects of Helicobacter pylori infection on murine autoimmune gastritis. Gut 52, 1102–1110.
Rokka S., Myllykangas S., and Joutsjoki V. 2008. Effect of specific colostral antibodies and selected lactobacilli on the adhesion of Helicobacter pylori on AGS cells and the Helicobacter-induced IL-8 production. Scand. J. Immunol. 68, 280–286.
Sachdeva A. and Nagpal J. 2009. Effect of fermented milk-based probiotic preparations on Helicobacter pylori eradication: a systematic review and meta-analysis of randomized-controlled trials. Eur. J. Gastroenterol. Hepatol. 21, 45–53.
Sakamoto I., Igarashi M., Kimura K., Takagi A., Miwa T., and Koga Y. 2001. Suppressive effect of Lactobacillus gasseri OLL 2716 (LG21) on Helicobacter pylori infection in humans. J. Antimicrob. Chemother. 47, 709–710.
Sartor R.B. 2005. Probiotic therapy of intestinal inflammation and infections. Curr. Opin. Gastroenterol. 21, 44–50.
Sgouras D., Maragkoudakis P., Petraki K., Martinez-Gonzalez B., Eriotou E., Michopoulos S., Kalantzopoulos G., Tsakalidou E., and Mentis A. 2004. In vitro and in vivo inhibition of Helicobacter pylori by Lactobacillus casei strain Shirota. Appl. Environ. Microbiol. 70, 518–526.
Sgouras D.N., Panayotopoulou E.G., Martinez-Gonzalez B., Petraki K., Michopoulos S., and Mentis A. 2005. Lactobacillus johnsonii La1 attenuates Helicobacter pylori-associated gastritis and reduces levels of proinflammatory chemokines in C57BL/6 mice. Clin. Diagn. Lab. Immunol. 12, 1378–1386.
Sheu B.S., Wu J.J., Lo C.Y., Wu H.W., Chen J.H., Lin Y.S., and Lin M.D. 2002. Impact of supplement with Lactobacillus- and Bifidobacterium-containing yogurt on triple therapy for Helicobacter pylori eradication. Aliment. Pharmacol. Ther. 16, 1669–1675.
Tien M.T., Girardin S.E., Regnault B., Le Bourhis L., Dillies M.A., Coppee J.Y., Bourdet-Sicard R., Sansonetti P.J., and Pedron T. 2006. Anti-inflammatory effect of Lactobacillus casei on Shigella-infected human intestinal epithelial cells. J. Immunol. 176, 1228–1237.
Tsai C.C., Hsih H.Y., Chiu H.H., Lai Y.Y., Liu J.H., Yu B., and Tsen H.Y. 2005. Antagonistic activity against Salmonella infection in vitro and in vivo for two Lactobacillus strains from swine and poultry. Int. J. Food Microbiol. 102, 185–194.
Ushiyama A., Tanaka K., Aiba Y., Shiba T., Takagi A., Mine T., and Koga Y. 2003. Lactobacillus gasseri OLL2716 as a probiotic in clarithromycin-resistant Helicobacter pylori infection. J. Gastroenterol. Hepatol. 18, 986–991.
Vitor J.M. and Vale F.F. 2011. Alternative therapies for Helicobacter pylori: probiotics and phytomedicine. FEMS Immunol. Med. Microbiol. 63, 153–164.
Wang F., Meng W., Wang B., and Qiao L. 2014. Helicobacter pylori-induced gastric inflammation and gastric cancer. Cancer Lett. 345, 196–202.
Yang Y.J., Chuang C.C., Yang H.B., Lu C.C., and Sheu B.S. 2012. Lactobacillus acidophilus ameliorates H. pylori-induced gastric inflammation by inactivating the Smad7 and NFkappaB pathways. BMC Microbiol. 12, 38.
Zhang L., Su P., Henriksson A., O’Rourke J., and Mitchell H. 2008. Investigation of the immunomodulatory effects of Lactobacillus casei and Bifidobacterium lactis on Helicobacter pylori infection. Helicobacter 13, 183–190.
Zou J., Dong J., and Yu X. 2009. Meta-analysis: Lactobacillus containing quadruple therapy versus standard triple first-line therapy for Helicobacter pylori eradication. Helicobacter 14, 97–107.
Author information
Authors and Affiliations
Corresponding author
Additional information
These authors contributed equally to this study.
Rights and permissions
About this article
Cite this article
Kim, JE., Kim, MS., Yoon, YS. et al. Use of selected lactic acid bacteria in the eradication of Helicobacter pylori infection. J Microbiol. 52, 955–962 (2014). https://doi.org/10.1007/s12275-014-4355-y
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12275-014-4355-y